Ligand validation:8KBK

MF6: (1S,3R,4R,6R,9S,11R,14R,15S,16R,18R)-4-(6-amino-9H-purin-9-yl)-9,11,15,16,18-pentahydroxy-2,5,8,10,12,17-hexaoxa-9lambda~5~,11lambda~5~-diphosphatricyclo[12.2.1.1~3,6~]octadecane-9,11-dione

MF6 is a Ligand Of Interest in 8KBK designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8KBK_MF6_B_201	43%	34%	0.195	0.918	0.76	1.82	1	10	3	0	100%	0.46
8KBK_MF6_A_201	40%	44%	0.217	0.93	0.72	1.42	-	6	1	0	100%	0.43
8KBJ_MF6_D_201	84%	47%	0.1	0.963	0.75	1.27	-	6	2	0	100%	0.58
7UAW_MF6_B_201	99%	33%	0.05	0.981	1.12	1.51	3	4	0	0	100%	1
8SMG_MF6_B_101	43%	35%	0.178	0.903	1.27	1.27	4	3	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.